Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -57.34% is 37% above its 5-year average of -91.71%, near the high end of its 5-year range (-511.41%–-25.39%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.25% above its 12-month average of -59.89%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -57.34%.
RETURN ON EQUITY (ROE)
-57.34%
RETURN ON EQUITY (ROE) AVG TTM
-59.89%
RETURN ON EQUITY (ROE) AVG 3Y
-53.32%
RETURN ON EQUITY (ROE) AVG 5Y
-91.71%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.25%
CURRENT VS 3Y AVG
-7.55%
CURRENT VS 5Y AVG
+37.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 686 covered companies
CURRENT VS SECTOR MEDIAN
-40.24%
vs the sector median at left
Satellos Bioscience Inc.
Market Cap
$10.44M
Return on Equity (ROE)
-57.34%
TTM Avg
-59.89%
3Y Avg
-53.32%
5Y Avg
-91.71%
Market Cap
$10.51M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$10.33M
Return on Equity (ROE)
N/A
TTM Avg
-652.54%
3Y Avg
-364.25%
5Y Avg
-252.47%
Market Cap
$10.55M
Return on Equity (ROE)
-252.37%
TTM Avg
-195.20%
3Y Avg
-116.68%
5Y Avg
-90.09%
Market Cap
$10.32M
Return on Equity (ROE)
N/A
TTM Avg
-22.56%
3Y Avg
-244.57%
5Y Avg
3710.91%
Market Cap
$10.65M
Return on Equity (ROE)
-177.35%
TTM Avg
-89.62%
3Y Avg
-75.99%
5Y Avg
-59.80%
Market Cap
$10.05M
Return on Equity (ROE)
N/A
TTM Avg
18596.99%
3Y Avg
9182.42%
5Y Avg
7349.85%
Market Cap
$10.94M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$10.96M
Return on Equity (ROE)
-506.63%
TTM Avg
-300.20%
3Y Avg
-300.20%
5Y Avg
-300.20%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.44M | -57.34% | -59.89% | -53.32% | -91.71% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A | -43.97% | -160.70% | -188.29% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.33M | N/A | -652.54% | -364.25% | -252.47% |
| Lifeward Ltd. (LFWD)vs › | $10.55M | -252.37% | -195.20% | -116.68% | -90.09% |
| Polyrizon Ltd. (PLRZ)vs › | $10.32M | N/A | -22.56% | -244.57% | 3710.91% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | -177.35% | -89.62% | -75.99% | -59.80% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.05M | N/A | 18596.99% | 9182.42% | 7349.85% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -477.54% | -207.60% | 64.51% | -22.91% |
| Caring Brands, Inc. (CABR)vs › | $10.96M | -506.63% | -300.20% | -300.20% | -300.20% |
| MetaVia Inc. (MTVA)vs › | $9.88M | -211.76% | -295.58% | -182.53% | -207.81% |
ROE
-57.3%
ROA
-52.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -57.34% |
| 2026-03-31 | -40.20% |
| 2025-12-31 | -89.52% |
| 2025-09-30 | -58.42% |
| 2025-06-30 | -53.94% |
| 2025-03-31 | -46.77% |
| 2024-12-31 | -56.22% |
| 2024-09-30 | -187.47% |
| 2024-06-30 | -80.17% |
| 2024-03-31 | -61.75% |
| 2023-12-31 | -38.74% |
| 2023-09-30 | -31.36% |
| 2023-06-30 | -25.39% |
| 2023-03-31 | -511.41% |
| 2022-12-31 | -345.31% |
| 2022-09-30 | -115.96% |
| 2022-06-30 | -262.67% |
| 2022-03-31 | -188.18% |
| 2021-12-31 | -146.73% |
| 2021-09-30 | -109.95% |
| 2021-03-31 | -698.43% |
| 2019-12-31 | -285.47% |
| 2019-09-30 | -110.27% |
